Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Relypsa, DSM Enter API Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Relypsa, DSM Enter API Supply Pact

Secures additional manufacturing capacity for Patiromer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Relypsa, Inc. has entered into a multi-year commercial manufacturing and supply agreement with DSM Fine Chemicals for the API for patiromer, the company’s novel polymer in development for the treatment of hyperkalemia. DSM Fine Chemicals is a business unit of the newly formed DPx Holding B.V., which also owns Patheon and Banner Life Sciences.
 
In addition to DSM, Relypsa also has an agreement with Lanxess Corp. for the supply of API. Both companies manufactured and supplied API for the clinical development program. Relypsa expects Lanxess to be the initial sole manufacturer named in its NDA but plans to submit a NDA supplement seeking approval for DSM as an additional manufacturer upon U.S. approval.
 
“We are very pleased to add DSM Fine Chemicals, a well-established contract manufacturer with significant experience in efficiently manufacturing polymers for therapeutic use, as a supplier of API for patiromer,” said Wilhelm Stahl, Ph.D., senior vice president pharmaceutical operations at Relypsa. “Engaging another supplier is an important milestone towards preparing to cover our projected commercial demand and improving our security of supplies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics